AlphAIalphai — Financial news for AI agents
stocktitan.netAUG 261 min read$EW

Edwards Lifesciences (NYSE: EW) exec may sell 1,240 shares

Edwards Lifesciences (EW) officer Wayne Markowitz filed a Rule 144 notice to sell 1,240 shares, valued at $113,417. The shares stem from restricted stock lapses. Markowitz previously sold 9,775 shares in the past three months. EW has 576.4M shares outstanding.

Original reporting
stocktitan.net
Published Aug 26, 2026, 8:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 6:19 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$EW
Neutral
high confidence
Mentioned
$EW
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$EWNeutralLow
01

Why it matters

The filing provides transparency on insider holdings but is unlikely to affect market dynamics.

02

Market read

Routine insider sale with minimal market impact.

03

What to watch

Potential upcoming earnings or product news not disclosed may influence insider timing.

Relevance 4/10Novelty 4/10Timing: reported Aug 26 2026

Background

Edwards Lifesciences filed a Rule 144 notice for officer Wayne Markowitz to sell a small block of shares.

Company-level read

Ticker impact

$EWNeutralHigh confidence
Context

Form 4 filing shows officer Wayne Markowitz may sell 1,240 EW shares worth $113,417, a routine insider sale.

Expected impact

Minimal, likely no material price change.

Evidence & confidence

Sale size is modest relative to 576M shares outstanding; typical insider transaction.

Market effects

Sector

None; insider sale does not affect medical device sector broadly.

Regional

None; limited to EW shareholders.

Global

None; isolated to the company.

Counterpoint

What could challenge this read

If insiders are selling, could signal concerns about future performance.

Key entities

  • Officer
    Wayne Markowitz

    Officer of Edwards Lifesciences filing Form 4.

  • Company
    Edwards Lifesciences Corp

    Medical device manufacturer listed on NYSE under EW.

Read at source← All news

Related articles

AUG 27
$EWHighAI 8/10

Edwards Lifesciences CVP Daveen Chopra sells $2.9m in stock

Edwards Lifesciences CVP Daveen Chopra sold 31,800 shares for $2.89m after exercising options. Shares were sold at $90.99-$91.76 each. Chopra now holds 44,324 shares. Edwards Lifesciences reported Q2 earnings of $0.78 EPS and $1.74B revenue, raising full-year outlook. Analysts updated price targets and ratings.

investing.com2 min
AUG 20
$EWMed

Should You Hold Edwards Lifesciences Stock in Your Portfolio?

Edwards Lifesciences (EW) reports growth in its TMTT and TAVR businesses, with Q2 2026 sales up 10.5% and 44.8% respectively. The company faces risks from currency fluctuations and competition. EW's stock gained 16.9% over the past year, outperforming its industry. Earnings yield is 3.3%, and the company expects 2026 gross margin near the lower end of its range.

zacks.com2 min
AUG 5
$EWMedAI 8/10

FTC Reaches $12 Million Settlement Over Alleged HSR Act Violations

The FTC proposed a settlement with Edwards Lifesciences and Genesis MedTech over alleged Hart-Scott-Rodino filing violations tied to Edwards’ July 2024 $115 million acquisition of JC Medical. The FTC says a $25 million Genesis non-voting share investment was additional deal consideration, making the combined value reportable. Edwards would pay $10 million and Genesis $2 million.

mondaq.com6 min
AUG 3
$EWMedAI 8/10

Edwards Reports Q2 Sales Climb 14% to $1.74B

Edwards Lifesciences (NYSE: EW) reported Q2 revenue of $1.74B, up 14% year over year, and adjusted EPS of 78 cents, above expectations. Full-year sales guidance was raised to 10%-11%. TAVR sales grew 11% to $1.26B. CMS draft Medicare coverage could expand TAVR access, with a final decision expected in September.

ocbj.com5 min
JUL 27
$EWMedAI 8/10

Edwards Lifesciences Wins FDA Clearance for Ecliptis Left Atrial Appendage Clip

Edwards Lifesciences said the FDA cleared its Ecliptis left atrial appendage exclusion system for use during cardiac surgery to help prevent clot formation in atrial fibrillation. The company plans a preliminary launch later this year and expects to leverage its surgical valve footprint. The article also notes FDA Breakthrough designation for Aidoc’s AI and OTC Dexcom Stelo clearance for children.

thehealthcaretechnologyreport.com3 min